Actively Recruiting
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-02-12
260
Participants Needed
1
Research Sites
157 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer
CONDITIONS
Official Title
A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and ability to follow study visits and procedures
- Male or female aged 18 to 75 years
- Histologically or cytologically confirmed advanced colorectal cancer
- Disease progressed on or unsuitable/refused standard therapy
- Adequate organ function
- At least one measurable lesion per RECIST v1.1 criteria
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Life expectancy of 3 months or more
- Agree to use effective contraception during treatment and for 6 months after if of childbearing potential
You will not qualify if you...
- Pregnant or breastfeeding women or planning pregnancy before, during, or within 6 months after treatment
- Active epileptic seizures or active central nervous system metastases
- Significant cardiovascular or cerebrovascular disease
- Severe lung diseases including interstitial pneumonia or radiation pneumonitis requiring treatment
- History of allergies, asthma, or atopic dermatitis
- Large pleural effusion or ascites
- Active autoimmune disease needing systemic therapy within 2 years
- History of organ or stem cell transplantation
- Known hypersensitivity to study drugs or excipients
- Previous severe toxicity from immune checkpoint inhibitors or Bevacizumab requiring stopping treatment
- Unresolved grade >1 toxicity from prior cancer therapies (except some mild conditions)
- Active uncontrolled bleeding or bleeding disorders
- Major surgery within 4 weeks before starting study drug
- Positive HIV, active hepatitis B or C, or tuberculosis
- Severe or uncontrolled infections or unexplained fever within 2 weeks before treatment
- Diagnosis of another cancer within 5 years except certain treated skin or prostate cancers
- Any condition or history that may affect safety, consent, compliance, or safety evaluation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Union Hospital, Tongji Medical College, Huazhong University Hospital
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
Y
yanxi pu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here